---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-005981"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:53:29.729172+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences reports expected Q1 2024 net loss of ~$2.8M, zero revenue; files for public offering

## Summary
- Expected Q1 2024 net loss of approx. $2.8M vs. $2.9M in Q1 2023; zero revenue in both quarters.
- As of March 31, 2024, total assets ~$5.0M, cash ~$1.1M, working capital only ~$54k.
- Filed Form S-1/A for public offering of common stock and warrants; terms not disclosed.
- Preliminary results are unaudited and subject to final closing and audit adjustments.

## SEC filing metadata
- accession: 0001654954-24-005981
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/0001654954-24-005981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-005981
- JSON: https://secwatch.observer/filing/0001654954-24-005981.json
- Plain text: https://secwatch.observer/filing/0001654954-24-005981.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the fiscal quarter ended March 31, 2024 results: net income We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024.
  - Period: the fiscal quarter ended March 31, 2024
  - Net income: We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024
  - Result: preliminary results
  source text: On May 10, 2024, ENDRA Life Sciences Inc. (the “Company”) filed a Registration Statement (the “Prospectus”) on Form S-1/A (No. 333-278842) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to a public offering (the “Offering”) of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock. The Prospectus contains select preliminary unaudited estimated financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/0001654954-24-005981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.